Nuwellis (NUWE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Special meeting scheduled for August 4, 2025, to vote on four key proposals, including warrant exercise, share authorization increase, reverse stock split, and potential adjournment to solicit more proxies.
The meeting will be held virtually, allowing shareholders to attend, vote, and ask questions online.
Only shareholders of record as of June 9, 2025, are eligible to vote.
Voting matters and shareholder proposals
Proposal 1: Approve issuance of up to 1,599,214 shares upon exercise of warrants from a June 2025 financing, in compliance with Nasdaq rules.
Proposal 2: Approve amendment to increase authorized common stock from 100,000,000 to 200,000,000 shares.
Proposal 3: Approve a reverse stock split at a ratio between 1-for-5 and 1-for-70, at the Board's discretion, to maintain Nasdaq listing.
Proposal 4: Authorize adjournment of the meeting to solicit additional proxies if needed for Proposals 1, 2, or 3.
Board unanimously recommends voting FOR all proposals.
Board of directors and corporate governance
Board retains discretion on the timing and ratio of the reverse stock split within a 12-month window after approval.
No directors or executive officers have substantial interests in the warrant exercise proposal beyond their shareholdings.
Security ownership table provided for directors, officers, and major shareholders as of June 9, 2025.
Latest events from Nuwellis
- Q4 revenue and margin gains, strategic moves, and new leadership set up 2026 growth.NUWE
Q4 202520 Mar 2026 - Innovative fluid management platform targets $4.2B market with strong clinical and financial momentum.NUWE
Investor presentation10 Mar 2026 - Registering 4.28M shares for resale, proceeds from warrant exercises support working capital.NUWE
Registration Filing4 Feb 2026 - Q2 revenue up 6% to $2.2M, gross margin 67.2%, but cash runway and losses remain concerns.NUWE
Q2 20241 Feb 2026 - Q3 net income reached $2.4M, with improved margins and major reimbursement gains set for 2025.NUWE
Q3 202415 Jan 2026 - Improved margins and CMS reimbursement set stage for outpatient growth despite lower Q4 revenue.NUWE
Q4 202425 Dec 2025 - Flexible $25M shelf offering targets R&D and growth in fluid management devices.NUWE
Registration Filing16 Dec 2025 - Proxy seeks approval for director elections, reverse split, and auditor ratification to ensure compliance.NUWE
Proxy Filing2 Dec 2025 - Key votes include director elections and a reverse stock split to support Nasdaq compliance.NUWE
Proxy Filing2 Dec 2025